Mono Pharmacare Q2 FY26 – Sharp Decline Across Revenue and Earnings

Mono Pharmacare reported a challenging September 2025 quarter, with steep YoY declines in revenue, profitability, and EPS, indicating margin pressure and weaker business performance. • Sales: ↓ 24% YoY to ₹66.3 crore (vs ₹87.2 crore in Sep 2024) • EBIDT: ↓ 62% YoY to ₹1.78 crore (vs ₹4.74 crore) • Net Profit: ↓ 99% YoY to ₹0.02 crore (vs ₹2.30 crore) • EPS: ↓ 99% YoY to ₹0.01 (vs ₹1.30) At a price of ₹21.0, market cap ₹37.0 crore, and PE 44.6, Mono Pharmacare faces significant financial slowdown, with profitability and margins under notable pressure.